Volume 7.27 | Jul 16

Mammary Cell News 7.27 July 16, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
New Drug Combo Could Make Cancer More Sensitive to Chemo
Scientists identified one particular component of a network–a protein called Bcl-xL–which helps the cancer cells survive treatment by blocking the self-destruct process that normally kills cells when treated with chemotherapy drugs. [Press release from Cancer Research UK discussing online prepublication in Cancer Cell]
Press Release | Full Article | Graphical Abstract
Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
PUBLICATIONS (Ranked by impact factor of the journal)

The Cell Cycle Regulator 14-3-3σ Opposes and Reverses Cancer Metabolic Reprogramming
Investigators showed that 14-3-3σ regulates cancer metabolic reprogramming and protects cells from tumorigenic transformation. 14-3-3σ opposed tumor-promoting metabolic programs by enhancing c-Myc poly-ubiquitination and subsequent degradation. [Nat Commun] Abstract | Press Release

DNA Methylation of Estrogen-Regulated Enhancers Defines Endocrine Sensitivity in Breast Cancer
Researchers showed that DNA hypermethylation occurs predominantly at estrogen-responsive enhancers and is associated with reduced expression of estrogen receptor (ESR1) binding and decreased gene expression of key regulators of ESR1 activity, thus providing a novel mechanism by which endocrine response is abated in ESR1-positive breast cancers. [Nat Commun] Full Article

Dysregulated Protease Activated Receptor 1 (PAR1) Promotes Metastatic Phenotype in Breast Cancer through HMGA2
PAR1 expression increased spheroid formation and the level of stemness markers and self-renewal capacity in human breast cancer cells. [Oncogene] Abstract

Acquisition of Estrogen Independence Induces TOB1-Related Mechanisms Supporting Breast Cancer Cell Proliferation
Depletion of TOB1 selectively promoted G1 phase arrest and sensitivity to AKT and mammalian target of rapamycin inhibitors in estrogen-independent cells but not in estrogen-dependent cells. [Oncogene] Abstract

Wild-Type N-Ras, Overexpressed in Basal-Like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation
Researchers identified N-Ras-responsive genes, most of which encode chemokines; e.g., IL8. Expression levels of these chemokines and N-RAS in tumors correlate with outcome. N-Ras, but not K-Ras, induces IL-8 by binding and activating the cytoplasmic pool of JAK2; IL-8 then acts on both the cancer cells and stromal fibroblasts. [Cell Rep] Full Article | Graphical Abstract | Press Release

Fe65 Suppresses Breast Cancer Cell Migration and Invasion through Tip60 Mediated Cortactin Acetylation
Fe65 is a brain-enriched adaptor protein known for its role in the action of the Aβ amyloid precursor protein in neuronal cells and Alzheimer’s disease, but little is known about its functions in cancer cells. The authors present a role of Fe65 in suppressing breast cancer cell migration and invasion. [Sci Rep] Full Article

Analysis of Gene Expression of Secreted Factors Associated with Breast Cancer Metastases in Breast Cancer Subtypes
The authors characterized the relative gene expression of the five secreted molecules and their associated receptors in the basal, human epidermal growth factor receptor 2 positive, luminal A, and luminal B subtypes using high throughput data from tumor samples in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium. [Sci Rep] Full Article

Estrogen Receptor α Regulates Non-Canonical Autophagy that Provides Stress Resistance to Neuroblastoma and Breast Cancer Cells and Involves BAG3 Function
Researchers characterized tumor cell lines ectopically expressing estrogen recepter (ER)α or ERβ as well as the breast cancer-derived MCF-7 cell line endogenously expressing ERα but being ERβ negative. They showed that ERα-expressing cells have a higher autophagic activity than cells expressing ERβ and cells lacking ER expression. [Cell Death Dis] Full Article

LIN28A Modulates Splicing and Gene Expression Programs in Breast Cancer Cells
Scientists identified heterogeneous nuclear ribonucleoprotein A1, a protein with multiple roles in mRNA metabolism, as a LIN28 interacting partner. Results reveal these proteins regulate alternative splicing and steady state mRNA expression of genes implicated in aspects of breast cancer biology. [Mol Cell Biol] Abstract


Phase II Study of Lapatinib in Combination with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging
Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2–positive metastatic breast cancer. Researchers tested the combination in the earlier-line setting and explored the predictive value of [18F]fluorodeoxyglucose positron emission tomography for clinical outcomes. [J Clin Oncol] Abstract

Phase I/II Trial of Neoadjuvant Sunitinib Administered with Weekly Paclitaxel/Carboplatin in Patients with Locally Advanced Triple-Negative Breast Cancer
Investigators evaluated the feasibility and efficacy of adding sunitinib to paclitaxel/carboplatin in the neoadjuvant therapy of patients with triple-negative breast cancer. [Breast Cancer Res Treat] Abstract

Request your FREE copy of STEMCELL Technologies' new 2015 catalog!
The Role of Inflammation in Progression of Breast Cancer: Friend or Foe?
The authors review some of the most significant findings for the role of the immune system and inflammatory response in breast cancer progression. Focusing on how the inflammatory microenvironment may be involved in the progression of pre-invasive ductal carcinoma in situ to invasive breast cancer. [Int J Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Cancer Research UK and Cancer Research Technology Announce Partnership with Monopar Therapeutics to Develop New Oncology Compound
Cancer Research UK and Cancer Research Technology have reached agreement with Monopar Therapeutics LLC to take forward Monopar’s experimental antibody treatment HuATN-658 into clinical trials in cancer patients with advanced solid tumors. [Cancer Research UK] Press Release

Georgetown Lombardi Comprehensive Cancer Center and John Theurer Cancer Center Launch Transformational Collaboration to Advance Cancer Research
Georgetown Lombardi Comprehensive Cancer Center and John Theurer Cancer Center, part of Hackensack University Medical Center, announced that they have developed a joint cancer research agenda as part of a multi-year plan to form a National Cancer Institute recognized cancer consortium. [Georgetown Lombardi Comprehensive Cancer Center (PR Newswire Association LLC)] Press Release

Ludwig Cancer Research and University of Oxford Launch Cancer Immunotherapy Spinout
Isis Innovation, the University of Oxford’s technology commercialization company, and Ludwig Cancer Research announced the launch of a new spinout company, iOx Therapeutics. iOx Therapeutics will develop a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford’s Weatherall Institute of Molecular Medicine. [Ludwig Cancer Research] Press Release

From our sponsor: Learn how to form and isolate neural rosettes more efficiently. Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cancer and Metabolism 2015
September 28-30, 2015
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Research Fellow (Fred Hutchinson Cancer Research Center)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Associate/ Assistant Professor – Breast Cancer (University of Chicago)

Senior Product Manager – Breast Cancer (Celgene Corporation)

PhD Position – Anti-Cancer Nano-Particle Drug Testing (University of Southern Denmark)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Postdoctoral Researcher – Breast Cancer (University of Oxford)

Postdoctoral Fellow – Oncolytic Viruses (Mayo Clinic – Rochester)

Postdoctoral Positions – Breast Cancer (University of Texas MD Anderson Cancer Center)

Assistant/Associate/Full Professor – Oncology (Shanghai Jiao Tong University School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us